Avinash Kundadka Kudva

Dr. Avinash Kundadka Kudva

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Bioorganic Chemistry
Verified
Journal Article
Closed access
RGRamesh S. Gani
Ramesh S. Gani
AKAvinash Kundadka Kudva
Avinash Kundadka Kudva
KTKarabasanagouda Timanagouda
Karabasanagouda Timanagouda
RARaghuveer
Raghuveer
SMSalma Begum Hussain Mujawar
Salma Begum Hussain Mujawar
SRShamprasad Varija Raghu
Shamprasad Varija Raghu

16 September 2022 in 3 Biotech
Verified
Journal Article
Closed access
PDF file
NKNishal Keshav
Nishal Keshav
RARamyalakshmi Ammankallu
Ramyalakshmi Ammankallu
SHShashidhar
Shashidhar
JPJagdish Gopal Paithankar
Jagdish Gopal Paithankar
MBManjeshwar Shrinath Baliga
Manjeshwar Shrinath Baliga
SRShamprasad Varija Varija Raghu
Shamprasad Varija Varija Raghu

1 April 2024 in Life
Verified
Journal Article
Open access
PDF file
VRVijay Radhakrishnan
Vijay Radhakrishnan
Upendar Rao GollaUpendar Rao Golla
Upendar Rao Golla
AKAvinash Kundadka Kudva
Avinash Kundadka Kudva
The clinical signs of multiple myeloma, a plasma cell (PC) dyscrasia, include bone loss, renal damage, and paraproteinemia. It can be defined as the uncontrolled growth of malignant PCs within the bone marrow. The distinctive bone marrow milieu that regulates the progression of myeloma disease involves interactions between plasma and stromal cells, and myeloid and lymphoid cells. These cells affect the immune system independently or because of a complicated web of interconnections, which promotes disease development and immune evasion. Due to the importance of these factors in the onset of disease, various therapeutic strategies have been created that either target or improve the immunological processes that influence disease progression. The immune system has a role in the mechanism of action of multiple myeloma treatments. The main contributions of immune cells to the bone marrow microenvironment, as well as how they interact and how immune regulation might lead to therapeutic effects, are covered in this study.

27 October 2021 in Food & Function
Verified
Journal Article
Closed access
PDF file
SRShamprasad Varija Varija Raghu
Shamprasad Varija Varija Raghu
AKAvinash Kundadka Kudva
Avinash Kundadka Kudva
SRSuresh Rao
Suresh Rao
KPKrishna Prasad
Krishna Prasad
JMJayesh Mudgal
Jayesh Mudgal
MBManjeshwar Shrinath Baliga
Manjeshwar Shrinath Baliga
Chemobrain or chemofog is one of the important but less investigated side effects, where the cancer survivors treated with chemotherapy develop long-term cognitive impairments, affecting their quality of life. The biological mechanisms triggering the development of chemobrain are largely unknown. However, a literature study suggests the generation of free radicals, oxidative stress, inflammatory cytokines, epigenetic chromatin remodeling, decreased neurogenesis, secretion of brain-derived neurotropic factor (BDNF), dendritic branching, and neurotransmitter release to be the cumulative contributions to the ailment. Unfortunately, there is no means to prevent/mitigate the development and intensity of chemobrain. Given the lack of effective prevention strategies or treatments, preclinical studies have been underway to ascertain the usefulness of natural products in mitigating chemobrain in the recent past. Natural products used in diets have been shown to provide beneficial effects by inhibition of free radicals, oxidative stress, inflammatory processes, and/or concomitant upregulation of various cell survival proteins. For the first time, this review focuses on the published effects of astaxanthin, omega-3 fatty acids, ginsenoside, cotinine, resveratrol, polydatin, catechin, rutin, naringin, curcumin, dehydrozingerone, berberine, C-phycocyanin, the higher fungi Cordyceps militaris, thyme (Thymus vulgaris) and polyherbal formulation Mulmina™ in mitigating cognitive impairments in preclinical models of study, and also addresses their potential neuro-therapeutic mechanisms and applications in preventing/ameliorating chemobrain.

21 July 2017 in New Journal of Chemistry
Verified
Journal Article
Closed access
PDF file
SBS. Shashidhar Bharadwaj
S. Shashidhar Bharadwaj
BPBoja Poojary
Boja Poojary
MSMadan Kumar S
Madan Kumar S
KBKullaiaha Byrappa
Kullaiaha Byrappa
GNGovinahalli Shivashankara Nagananda
Govinahalli Shivashankara Nagananda
BDB. L. Dhananjaya
B. L. Dhananjaya
Our aim with the present work was to design and synthesize quinoline Schiff bases and quinolinyloxadiazole hybrid molecules and assess them for in vitro antioxidant activities and antimicrobial properties against clinical isolates. Synthesized compounds were characterized using FT-IR, 1H NMR, 13C NMR, mass spectra, and single crystal X-RD techniques. All compounds viz., 4a–g and 5a–g were efficiently synthesized in good yields in ranges of 76–84% and 80–85%, respectively. Newly synthesized compounds were screened for their antioxidant and antimicrobial potentials. Results were compared with standard antibacterial (amoxicillin and streptomycin) and antifungal (fluconazole) compounds which served as positive controls. Compounds 4b and 5g showed free radical scavenging activity of 26.55% (IC50 value 288.38 μg mL−1) and 27.22% (IC50 value of 167.69 μg mL−1), respectively. Compounds 4a, 4f, 5c, and 5e exhibited pronounced antimicrobial activity among all other synthesized compounds with zones of inhibition ranging between 10 ± 1 to 21 ± 1 mm and MIC 17 to 33.5 μg mL−1. Molecular docking studies of the synthesized compounds revealed good binding via hydrogen bond interactions with key residues on active sites as well as neighboring residues with an active site of glucosamine-6-phosphate (G6P) synthase, the target protein which is essential for formation of bacterial or fungal cell walls, and indicating inhibition of G6P synthase. Among the synthesized compounds 4f, 5c, and 5b show the least binding energies of −9.31, −6.7 and −6.21 kcal mol−1, respectively. Results from in silico investigation as well as in vitro antimicrobial studies suggest that the synthesized compounds may act as potential antimicrobial agents.

30 May 2021 in Indian Journal of Otolaryngology and Head & Neck Surgery
Verified
Journal Article
Closed access
PDF file
AKAvinash Kundadka Kudva
Avinash Kundadka Kudva
SRShamprasad Varija Varija Raghu
Shamprasad Varija Varija Raghu
PAPavan Kumar Achar
Pavan Kumar Achar
SRSuresh Rao
Suresh Rao
SSSucharitha Suresh
Sucharitha Suresh
MBManjeshwar Shrinath Baliga
Manjeshwar Shrinath Baliga